Home › Research › Health systems and care delivery
[P2–557]: HEALTH CARE USE AMONG NEWLY DIAGNOSED ALZHEIMER's (AD) PATIENTS IN A U.S. COMMERCIAL MEDICARE ADVANTAGE INSURANCE PLAN
Christopher Matthew Black, Vinay Mehta, Brady Dubin, Rezaul Karim Khandker, Baishali M. Ambegaonkar, Mark Marsico. Alzheimer s & Dementia, 2017-07-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Leveraging real-world data to better understand health care utilization patterns prior to and after incident AD diagnosis may help inform the clinical management of the disease. Medical and pharmacy claims data from a large, geographically diverse, commercial, US Medicare Advantage health plan, for the period 2009–2014, were used to identify cases of newly diagnosed AD. The following beneficiaries were eligible for inclusion in the analysis: aged ≥65 with medical and prescription drug coverage, a claims history of either ≥2 AD diagnostic codes or one diagnosis code and a prescription fill for a medication indicated to treat AD, and ≥24 months of continuous coverage in the health plan prior to and after a diagnosis. Descriptive statistics were used to estimate mean monthly health care utilization and total health plan costs in the two years prior to incident AD diagnosis. A control cohort of elderly individuals without any dementia type was constructed using a 1:1 exact match for age, gender, and geographic region. A cohort of 4,039 beneficiaries was identified for inclusion in the analysis, 72% of whom were female. Health care utilization and monthly Medicare expenditures trended upward approximately 6–12 months prior to the diagnosis, with a clear peak in the 30 days immediately prior to the incident diagnosis (i.e. index month). Increases in the mean number of monthly outpatient visits (80%), emergency room visits (502%), inpatient stays (829%) and medication use (22%) were observed in the index month, compared to the 12 months prior to index. Mean per-person expenditures were greater among the AD cohort relative to controls in the index month ($1,446 v $376) and in the 12 months prior to index ($3,993 v $3,449).
What this study adds
Evidence grade: Moderate
This study found that health care use and costs rise sharply in the month before a new Alzheimer's disease diagnosis in a Medicare Advantage plan. It does not test any treatment, cure, or prevention for Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Black, C. M., Mehta, V., Dubin, B., Khandker, R. K., Ambegaonkar, B. M., & Marsico, M. (2017). [P2–557]: HEALTH CARE USE AMONG NEWLY DIAGNOSED ALZHEIMER's (AD) PATIENTS IN A U.S. COMMERCIAL MEDICARE ADVANTAGE INSURANCE PLAN. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2017.06.1216
Vancouver
Black CM, Mehta V, Dubin B, Khandker RK, Ambegaonkar BM, Marsico M. [P2–557]: HEALTH CARE USE AMONG NEWLY DIAGNOSED ALZHEIMER's (AD) PATIENTS IN A U.S. COMMERCIAL MEDICARE ADVANTAGE INSURANCE PLAN. Alzheimer s & Dementia. 2017. doi:10.1016/j.jalz.2017.06.1216.
BibTeX
@article{black2017-a66c9ecc,
author = {Black, Christopher Matthew and Mehta, Vinay and Dubin, Brady and Khandker, Rezaul Karim and Ambegaonkar, Baishali M. and Marsico, Mark},
title = {{[P2–557]: HEALTH CARE USE AMONG NEWLY DIAGNOSED ALZHEIMER's (AD) PATIENTS IN A U.S. COMMERCIAL MEDICARE ADVANTAGE INSURANCE PLAN}},
journal = {Alzheimer s \& Dementia},
year = {2017},
doi = {10.1016/j.jalz.2017.06.1216},
url = {https://doi.org/10.1016/j.jalz.2017.06.1216}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Increases in the mean number of monthly outpatient visits (80%), emergency room visits (502%), inpatient stays (829%) and medication use (22%) were observed in the index month, compared to the 12 months prior to index.
Why it matters
This study found that health care use and costs rise sharply in the month before a new Alzheimer's disease diagnosis in a Medicare Advantage plan. It does not test any treatment, cure, or prevention for Alzheimer's disease.
Study details
- Evidence strengthModerate
How this study scored 29/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.2 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Mark Marsico: h-index 6 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Merck & Co., Inc., Rahway, NJ, USA (United States): institution h-index 926 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 29 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Related
Studies in the library that share something with this one. The line above each title says what.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.